Akebia Therapeutics (AKBA) Equity Average (2014 - 2026)

Akebia Therapeutics (AKBA) has 13 years of Equity Average data on file, last reported at $30.0 million in Q1 2026.

• Equity Average for Q1 2026 came in at $30.0 million, up 343.8% year-over-year; the trailing twelve-month figure through Mar 2026 was $30.0 million (up 343.8% YoY), and the FY2025 annual result was -$8.3 million, up 79.22% from the prior year.
• Equity Average declined to $30.0 million in Q1 2026 per AKBA's latest filing, from $37.1 million in the prior quarter.
• Over five years, Equity Average peaked at $48.3 million in Q1 2022 and troughed at -$49.8 million in Q4 2024.
• A 5-year average of -$166264.7 and a median of -$6.9 million in 2023 frame the typical range for Equity Average.
• The sharpest annual moves came in 2023 and 2026: Equity Average tumbled 618.97% in 2023, then soared 343.8% in 2026.
• A 5-year view of Equity Average shows it stood at $6.7 million in 2022, then plunged by 618.97% to -$35.0 million in 2023, then plunged by 42.26% to -$49.8 million in 2024, then jumped by 174.51% to $37.1 million in 2025, then fell by 19.16% to $30.0 million in 2026.
• Business Quant data shows AKBA's Equity Average at $30.0 million in Q1 2026, $37.1 million in Q4 2025, and $35.4 million in Q3 2025.